Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1303)	7/3/2000 10:18:43 AM
From: Torben Noerup Nielsen	Respond to of 52153

Peter, If anyone can beat the side-effects and the rebound from Ambien without reducing the potency, they have a winner. Big time. Thanks, Torben

To: Biomaven who wrote (1303)	7/3/2000 6:30:39 PM
From: Miljenko Zuanic	Respond to of 52153

Peter, Thanks for Ambient and Sonata numbers. I never have deep look on zopiclone. This is +15 years EU market drug. Any idea why drug isn’t on US market? One more thing, zopiclone have stereoselective pharmacokinetics (each enatiomer metabolize at different rate). In regards that (-)-zopiclone is anti-anxiolytic (which should be positive for insomnia therapy) what are chance, in your view, that (+)-zopiclone (as enantiomer who stay longer in blood) will not potentate side effects (hangover for instance) and at the some time miss (-)-zopiclone good property. Regards the +25 PII NBI trials I have hypothetical explanation. Insomnia isn’t disease and symptoms have many different causes: medication use, emotional stress, anxiety and depression, fear and nervousness,… . So, NBIX decided that testing drug in more than several specific situations, different pts population (ages), drug-drug interactions, acute and chronic dosing, as well as further studies of the different doses (pharmacokinetic) is good why to get more data on drug potential and how to progress with pivotal trials (if at all). I do not have problems with this approach as long as main course is on track. Miljenko